Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.
Liquidia Corporation (LQDA) is a biopharmaceutical innovator leveraging its proprietary PRINT® Technology to develop precision therapies for pulmonary hypertension and rare cardiopulmonary conditions. This page aggregates official company announcements, providing stakeholders with timely updates on clinical advancements, regulatory milestones, and strategic initiatives.
Investors and researchers will find curated press releases detailing progress in Liquidia’s pipeline, including YUTREPIA™ inhalation powder development, FDA communications, and technology licensing agreements. Content spans clinical trial results, manufacturing updates, and partnership announcements with global pharmaceutical entities.
Key categories include treatment efficacy studies, regulatory filings, intellectual property developments, and operational expansions. All materials adhere to factual reporting standards, ensuring reliable insights into the company’s scientific and business trajectory.
Bookmark this page for streamlined access to Liquidia’s latest verified updates. Combine regular visits with professional financial counsel to inform your investment strategy.
Liquidia Corporation (LQDA) announced a partial judgment in its favor regarding U.S. Patent No. 9,604,901 in ongoing litigation with United Therapeutics Corporation (UTC) under the Hatch-Waxman Act. The court's decision acknowledged Liquidia’s non-infringement of the patent, while UTC retains appellate rights. This ruling allows the ongoing regulatory stay of YUTREPIA™ (treprostinil) inhalation powder approval by the FDA to continue under U.S. Patent No. 9,593,066. The trial is scheduled for March 28-30, 2022.
Liquidia Corporation (NASDAQ: LQDA) has announced that its Chief Financial Officer, Michael Kaseta, will speak at the Jefferies 2021 Virtual London Healthcare Conference from November 16-19, 2021. The insightful fireside chat will be available on-demand from 8:00 a.m. GMT on November 18, 2021, for registered participants. Investors can access the webcast on Liquidia's website, which will remain archived for 30 days post-event. Liquidia focuses on the development of innovative therapies for pulmonary hypertension, including YUTREPIA™, an inhalation powder treatment.
Liquidia Corporation (NASDAQ: LQDA) announced the FDA granted tentative approval for YUTREPIA™ (treprostinil) inhalation powder, intended for treating pulmonary arterial hypertension (PAH). This approval, which confirms YUTREPIA's compliance with safety, quality, and efficacy standards, is a pivotal step toward market introduction. However, final approval awaits the resolution of ongoing litigation with United Therapeutics, impacting the commercial launch timeline, potentially slated for October 2022. YUTREPIA aims to provide a user-friendly alternative to existing therapies, targeting a significant market with sales exceeding $480 million.
Liquidia Corporation (LQDA) reported Q3 2021 financial results, highlighting a rise in Treprostinil Injection adoption among patients and payers, which doubled the patient count since May 2021. Revenue for Q3 was $3.2 million, compared to zero in Q3 2020, driven by a promotion agreement with Sandoz. However, revenue was impacted by a reduction in profit split percentage. The net loss decreased to $7.3 million, or $0.14 per share, from $15.0 million in Q3 2020. The FDA completed pre-approval inspections for LIQ861, with a decision expected by November 7, 2021.
Liquidia Corporation (NASDAQ: LQDA) achieved a favorable ruling from the U.S. Patent Trial and Appeal Board (PTAB) in its patent dispute with United Therapeutics Corporation. The PTAB deemed seven of the nine claims of U.S. Patent No. 9,604,901 unpatentable, leaving only narrower claims 6 and 7. This decision does not resolve ongoing litigation under the Hatch-Waxman Act regarding LIQ861, an investigational treatment for pulmonary arterial hypertension. Liquidia aims to commercialize LIQ861 following resolution of the litigation.
Liquidia Corporation (NASDAQ: LQDA) announced that CEO Damian deGoa will present at the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. The presentation will be virtual and available on-demand in the Investors section of Liquidia's website starting at 7:00 a.m. ET on September 13, 2021. It will remain accessible for 30 days post-conference. Liquidia focuses on the development of products for pulmonary hypertension using its PRINT® Technology.
Liquidia Corporation (NASDAQ: LQDA) announced that the FDA has completed a Pre-Approval Inspection (PAI) of its Morrisville, NC facility for the New Drug Application (NDA) of LIQ861 (treprostinil) inhalation powder. The inspection, which lasted five days and concluded on August 13, resulted in no Form 483 observations, marking a positive milestone for the company. The NDA, resubmitted on June 2, includes necessary clarifications and is under FDA review, with a PDUFA goal date set for November 7, 2021. The inspection supports Liquidia's proprietary PRINT® technology for enhanced drug delivery.
Liquidia Corporation (NASDAQ: LQDA) announced that the U.S. Patent Trial and Appeal Board (PTAB) has initiated inter partes review (IPR) of United Therapeutics' U.S. Patent No. 10,716,793. The PTAB indicated a reasonable likelihood of Liquidia succeeding in demonstrating the patent's unpatentability. This development could advance Liquidia's efforts to introduce LIQ861, an inhaled dry powder formulation of treprostinil, to treat pulmonary arterial hypertension (PAH). The FDA is reviewing the LIQ861 New Drug Application with a goal date set for November 7, 2021.
Liquidia Corporation (NASDAQ: LQDA) announced significant developments in its recent press release. It launched subcutaneous delivery of Treprostinil Injection, effectively doubling the market potential for this treatment. The company has also resubmitted its New Drug Application (NDA) for LIQ861, which received FDA acceptance for review, with a PDUFA goal date set for November 7, 2021. Financially, Liquidia has improved its balance sheet, reducing annual spending and increasing cash resources to $67.9 million as of June 30, 2021, while reporting revenue of $3.4 million in Q2 2021.
Liquidia Corporation (NASDAQ: LQDA) will report its second quarter 2021 financial results on August 10, 2021. A conference call and webcast are scheduled for 8:30 a.m. EDT, where the company will discuss financial outcomes and provide a corporate update. Interested parties can access the call via telephone or the webcast available on Liquidia's website. The company focuses on developing treatments for pulmonary hypertension through its PRINT® Technology, with ongoing projects like LIQ861 and Treprostinil Injection.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
